Powder: -20°C for 3 years | In solvent: -80°C for 1 year
PLX7904 (PB04) 是一种有效且选择性的悖论破坏剂 RAF 抑制剂,可抑制突变 BRAF 黑色素瘤细胞中 ERK1/2 的激活。在表达突变体 RAS 的细胞中,对 BRAFV600E 的IC50值约为 5 nM。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 413 | 现货 | ||
2 mg | ¥ 588 | 现货 | ||
5 mg | ¥ 913 | 现货 | ||
10 mg | ¥ 1,490 | 现货 | ||
25 mg | ¥ 2,680 | 现货 | ||
50 mg | ¥ 3,950 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 973 | 现货 |
产品描述 | PLX7904 (PB04), also known as PB04, is a potent and selective paradox-breaker RAF inhibitor. It is able to efficiently inhibit activation of ERK1/2 in mutant BRAF melanoma cells but does not hyperactivate ERK1/2 in mutant RAS-expressing cells. |
靶点活性 | BRAF:5 nM |
体外活性 | PLX7940 is able to efficiently inhibit activation of ERK1/2 in mutant BRAF melanoma cells but does not hyperactivate ERK1/2 in mutant RAS-expressing cells. Consistent with ERK1/2 re-activation driving the re-acquisition of malignant properties, PLX7904 promotes apoptosis and inhibits entry into S phase and anchorage-independent growth in mutant N-RAS mediated vemurafenib-resistant cells. PLX7904 is also evaluated in the human SCC cell line A431 and the human breast adenocarcinoma cell line SKBR3 as these cells achieve MAPK pathway activation by upstream signals feeding into RAS (through overexpression of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2), respectively)[1][2]. |
体内活性 | PLX7904 inhibits the COLO205 xenograft growth in eight mice per group[1]. |
细胞实验 | Cells are treated with PB04(PLX7904) at different concentrations (0, 0.05, 0.1, 1, 5 μM) for 24 h. Cells are lysed and analyzed by Western blotting with phospho-MEK1/2, total MEK1/2, phospho-ERK1/2 and total ERK1/2 antibodies. (Only for Reference) |
别名 | PB04 |
分子量 | 512.53 |
分子式 | C24H22F2N6O3S |
CAS No. | 1393465-84-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ethanol: < 1 mg/mL (insoluble or slightly soluble)
H2O: < 1 mg/mL (insoluble or slightly soluble)
DMSO: 100 mg/mL (195.11 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 1.9511 mL | 9.7555 mL | 19.5111 mL | 48.7776 mL |
5 mM | 0.3902 mL | 1.9511 mL | 3.9022 mL | 9.7555 mL | |
10 mM | 0.1951 mL | 0.9756 mL | 1.9511 mL | 4.8778 mL | |
20 mM | 0.0976 mL | 0.4878 mL | 0.9756 mL | 2.4389 mL | |
50 mM | 0.039 mL | 0.1951 mL | 0.3902 mL | 0.9756 mL | |
100 mM | 0.0195 mL | 0.0976 mL | 0.1951 mL | 0.4878 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
PLX7904 1393465-84-3 MAPK Raf PB04 Inhibitor inhibit PB-04 Raf kinases PLX-7904 PB 04 PLX 7904 inhibitor